Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT05808608 trial: what clinicians have said so far
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
- NCT05808608 ↗
- Active, not recruiting
- Hao Zeng
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT05808608 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05808608 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built | |
| 1 post on Bluesky, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Efficacy and Safety of First-Line Cadonilimab Plus Axitinib in Patients With Advanced Special Pathological Type Renal Cell Carcinoma: A Prospective, Multi-center, Phase Ib/II Trial
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Renal Cell Carcinoma; First-line Treatment; Non Clear Cell Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma
- Interventions
- AK104; Axitinib
- Arms
- Combination treatment group · Experimental
- Enrollment
- 37
- Primary outcomes
- Phase Ib Safety Assessment
- Phase II Efficacy Assessment: ORR
- Sponsor
- Hao Zeng
- Start
- Nov 17, 2023
- Primary completion
- Apr 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05808608 · updated Apr 7, 2026
Publications
linked from the registry- Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, Fernandez-Pello S, Giles RH, Hofmann F, Hora M, Klatte T, Kuusk T, Lam TB, Marconi L, Powles T, Tahbaz R, Volpe A, Bex A. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022 Oct;82(4):399-410. doi: 10.1016/j.eururo.2022.03.006. Epub 2022 Mar 26. PubMed 35346519
- Diaz-Montero CM, Rini BI, Finke JH. The immunology of renal cell carcinoma. Nat Rev Nephrol. 2020 Dec;16(12):721-735. doi: 10.1038/s41581-020-0316-3. Epub 2020 Jul 30. PubMed 32733094
- Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. PubMed 29562145
- 2022 ASCO # Oral abstract 106.